PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF REPLACING PCV13 WITH PCV15 IN THE NATIONAL IMMUNIZATION PROGRAM IN SAUDI ARABIA

被引：0
|
作者：
Huang, M. [1 ]
Weaver, J. [2 ]
Albassam, G. [3 ]
Akel, R. [4 ]
Chhabra, N. [5 ]
Ranjan, S. [5 ]
Gupta, S. [6 ]
Ugrekhelidze, D. [7 ]
机构：
[1] Merck & Co Inc, Merck Res Labs, Rahway, NJ USA
[2] Merck & Co Inc, Rahway, NJ USA
[3] MSD, Riyadh, Saudi Arabia
[4] MSD, Dubai, U Arab Emirates
[5] CHEORS, North Wales, PA USA
[6] CHEORS, Patna, BR, India
[7] MSD, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE562
引用
收藏
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF REPLACING PCV13 WITH PCV15 IN THE PEDIATRIC NATIONAL IMMUNIZATION PROGRAM OF GREECE
    Gountas, I
    Yfantopoulos, N.
    Trimis, G.
    Boutselakou, E.
    Poughias, L.
    Karokis, A.
    VALUE IN HEALTH, 2023, 26 (12) : S136 - S137
  • [2] COST-EFFECTIVENESS OF SWITCHING FROM PCV13 TO PCV20 IN THE PORTUGUESE CHILDHOOD NATIONAL IMMUNIZATION PROGRAM
    Mota, C.
    Ta, A.
    Vinand, E.
    Teixeira, R.
    Ilic, A.
    Perdrizet, J.
    VALUE IN HEALTH, 2024, 27 (12)
  • [3] HEALTH ECONOMIC EVALUATION OF REPLACING PCV13 WITH PCV15 IN THE DANISH CHILDHOOD VACCINATION PROGRAMME
    Kantso, Roesgaard L.
    Pedersen, M.
    Leth, S.
    Huang, M.
    Vinfeldt, M.
    VALUE IN HEALTH, 2022, 25 (12) : S57 - S57
  • [4] A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia
    Lagoubi, Youness
    Sfar, Mohamed Tahar
    Gomez, Jorge A.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (05)
  • [5] COST-EFFECTIVENESS OF REPLACING THE SEQUENCE PCV13/PPV23 WITH PCV20 IN THE FRENCH ADULT PNEUMOCOCCAL VACCINATION PROGRAM
    Fievez, S.
    Blanc, E.
    Bougeois, M.
    Sivignon, M.
    Supiot, R.
    Vietri, J.
    Perdrizet, J.
    Bellier, L.
    VALUE IN HEALTH, 2023, 26 (12) : S78 - S78
  • [6] COST-EFFECTIVENESS OF PCV15 IN THE PEDIATRIC POPULATION FOR PREVENTING PNEUMOCOCCAL DISEASE IN FRANCE
    Breau-Brunel, M.
    Farge, G.
    Bensimon, L.
    Malik, T.
    Carette, J.
    VALUE IN HEALTH, 2024, 27 (12)
  • [7] Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013
    Sibak, Mohammed
    Moussa, Ibrahim
    El-Tantawy, Nasr
    Badr, Shaza
    Chaudhri, Irtaza
    Allam, Essam
    Baxter, Louise
    Freikha, Saiyed Abo
    Hoestlandt, Celine
    Lara, Carlos
    Hajjeh, Rana
    Munier, Aline
    VACCINE, 2015, 33 : A182 - A191
  • [8] Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians
    Dirmesropian, S.
    Wood, J. G.
    MacIntyre, C. R.
    Beutels, P.
    McIntyre, P.
    Menzies, R.
    Reyes, J. F.
    Chen, C.
    Newall, A. T.
    VACCINE, 2017, 35 (34) : 4307 - 4314
  • [9] COST-EFFECTIVENESS ANALYSIS OF PCV13 VS PCV10 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE IN THE VIETNAM PEDIATRIC POPULATION
    Nguyen, T.
    Cao, Thanh T.
    Phong, Nguyen L.
    Wannaadisai, W.
    Huang, L.
    VALUE IN HEALTH, 2024, 27 (12) : S74 - S74
  • [10] Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
    Perdrizet, Johnna
    Santana, Carlos Felipe S.
    Senna, Thais
    Alexandre, Rodrigo Fernandes
    de Almeida, Rodrigo Sini
    Spinardi, Julia
    Wasserman, Matt
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (04) : 1162 - 1172
12345